Back to results
US 2021/0228696 A1Published application
Use of anti-cd137 antibody drug conjugate (adc) in allogeneic cell therapy
AssigneeMagenta Therapeutics, Inc.
InventorsAnthony Boitano, Michael Cooke
Life of this patent
Estimating the term…
Abstract
The invention provides methods of using allogeneic cells in therapy by combining allogeneic cell therapy with anti-CD137 antibody drug conjugates (ADCs). Disclosed are methods of treating or preventing a host versus graft (HvG) rejection in a human subject receiving allogeneic cell therapy by administering to the human subject an anti-CD137 ADC.
Claims30
A method for treating or preventing rejection of allogeneic cells transplanted into a human subject, the method comprising
- (a) administering to the human subject a first amount of an allogeneic cell, wherein the first amount is sufficient to elicit a priming response to the allogeneic cell in the human subject;
- (b) administering an anti-CD137 antibody drug conjugate (ADC) to the human subject such that endogenous CD137+ activated T cells are depleted, wherein the anti-CD137 ADC comprises an anti-CD137 antibody, or antigen-binding fragment thereof, conjugated to a cytotoxin via a linker;
- and
- (c) administering a therapeutically effective amount of an allogeneic cell expressing a CAR to the human subject, wherein the allogeneic cell is the same type of allogeneic cell administered in (a), and wherein the CAR comprises an extracellular domain that binds to a tumor antigen, a transmembrane domain, and a cytoplasmic signaling domain;
- such that allogeneic cell rejection is treated or prevented in the human subject.
2 more elements
A method of treating or preventing rejection of allogeneic cells transplanted into a human subject, the method comprising
- (a) administering an anti-CD137 ADC to the human subject, wherein the anti-CD137 ADC comprises an anti-CD137 antibody, or antigen-binding fragment thereof, conjugated to a cytotoxin via a linker, and wherein the human subject is characterized as having activated T cells directed to an allogeneic cell that was previously administered to the human subject;
- and
- (b) administering a therapeutically effective amount of an allogeneic cell expressing a CAR to the human subject, wherein the allogeneic cell is the same type of allogeneic cell described in (a), and wherein the CAR comprises an extracellular domain that binds to a tumor antigen, a transmembrane domain, and a cytoplasmic signaling domain,
- such that rejection of the transplanted allogeneic cells is treated or prevented in the human subject.
1 more element
Dependencies are inferred from the claim text.